GSE137100

Identification of miRNAs as biomarkers of drug response of Pien Tze Huang in Hepatic Fibrosis Treatments

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

12 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Pien Tze Huang (PZH) is herbal traditional Chinese medicine which was widely utilized in Asia for hepatic diseases. We constructed two groups hepatic fibrosis mice model using CCl4, one group using PZH treatment and another group replacing PZH with double distilled water. All 12 mice were fed for 8 weeks and then killed to have their liver tissue taken out. Small RNA-seq were used to identify miRNAs of PZH medicine effect for hepatic fibrosis. We found the expression of these miRNAs (mmu-miR-205-5p, mmu-miR-3064-5p, mmu-miR-205-5p, mmu-miR-370-3p, mmu-miR-665-3p) were changed in PZH medicine treatment for hepatic fibrosis study. Furthermore, Hmga2 and Fgf9, miRNAs corresponding target genes (Sp4, Slc2a6, Tln2, Hmga2, Ank3, Pax9, Fgf9), have been reported association with hepatic fibrosis.

Overall design

We constructed two groups hepatic fibrosis mice model using CCl4, one group using PZH treatment and another group replacing PZH with double distilled water. Small RNA-seq were used to identify miRNAs of PZH medicine effect for hepatic fibrosis.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
12 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Publication context when PubMed identifiers are already known.

No match found

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.
  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Organism differs from search intent Mus musculus Search intent expects Homo sapiens. Organism came from Normalization rules.
  • Disease context Fibrosis, liver fibrosis Disease context came from Normalization rules.
  • Likely case group Liver fibrosis 12 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Fibrosis, Liver fibrosis.
  • Processed data is available for downstream review.

Cautions

  • Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Small RNA, miRNA, circRNA, or extracellular-vesicle RNA context downgraded for primary mRNA tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because non-human datasets are outside the selected human ranking intent.
  • Overall score capped because secondary RNA assays are not primary mRNA tissue RNA-seq.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Tissue. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

53 fields

Sample Group Preview

12 rows shown
Show Hide
Study totals: Case 12 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 12 rows shown
Group Role Accession Title Source / characteristics Reason
Liver fibrosis Case GSM4066924 Hepatic Fibrosis Control1 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066925 Hepatic Fibrosis Control2 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066926 Hepatic Fibrosis Control3 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066927 Hepatic Fibrosis Control4 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066928 Hepatic Fibrosis Control5 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066929 Hepatic Fibrosis Control6 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066930 Hepatic Fibrosis PZH1 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066931 Hepatic Fibrosis PZH2 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066932 Hepatic Fibrosis PZH3 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066933 Hepatic Fibrosis PZH4 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066934 Hepatic Fibrosis PZH5 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.
Liver fibrosis Case GSM4066935 Hepatic Fibrosis PZH6 Hepatic fibrosis mice model Strain: C57BL/6; Tissue: Liver; Cell type: Hepatic fibrosis Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.